FLUO.ST

FluoGuide A/S [FLUO.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

FLUO.ST Stock Summary

Top 10 Correlated Stocks

FLUO.ST

In the News

FLUO.ST Financial details

Company Rating
-
Market Cap
552.57M
Income
-38.38M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-15.99
Forward P/E
-
PEG
-85.95
P/S
-
P/B
35.7
P/C
-
P/FCF
-18.53
Quick Ratio
1.69
Current Ratio
3.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.19
EPS next Y
-
EPS next Q
-
EPS this Y
8.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
11.21%
SMA50
27.18%
SMA100
7.08%
Inst Own
-
Inst Trans
-
ROA
-164%
ROE
-167%
ROC
-2.49%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
43.55-99.8
52W High
-56.77%
52W Low
-0.47%
RSI
61.92
Rel Volume
0.73
Avg Volume
9.12K
Volume
6.68K
Perf Week
4.14%
Perf Month
35.02%
Perf Quarter
6.2%
Perf Half Y
0%
-
-
-
-
Beta
1.068
-
-
Volatility
0.95%, 3.61%
Prev Close
0.94%
Price
42.8
Change
0%

Something similar

Top by Market Cap
NVDA
LLY.DE
ABEC.DE
VTSAX
LLY
Same Sector
PLXP
0JDK.L
ACCA
4737.TW
REGN
Top Correlated Stocks
IVACC.ST
4919.TW
3057.TW
SML.L
XPF.L
Similar Market Cap
ANII.L
INF.PA
XLSR
TPVY
0R0V.L

Company Profile

Healthcare Medical - Instruments & Supplies
  • Volume Average 9.12K
  • Market Capitalization 552.57M
  • Employee 7
  • CEO Mr. Morten Albrechtsen B.B.A., BBA, M.D.
  • Headquarters Copenhagen,DK
  • IPO Date 2019-06-17
  • Website https://fluoguide.com

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.